CY1116693T1 - Συνδυασμος αζελαστινης και κυκλεσονιδης - Google Patents

Συνδυασμος αζελαστινης και κυκλεσονιδης

Info

Publication number
CY1116693T1
CY1116693T1 CY20151100813T CY151100813T CY1116693T1 CY 1116693 T1 CY1116693 T1 CY 1116693T1 CY 20151100813 T CY20151100813 T CY 20151100813T CY 151100813 T CY151100813 T CY 151100813T CY 1116693 T1 CY1116693 T1 CY 1116693T1
Authority
CY
Cyprus
Prior art keywords
cycloneside
azelastin
combination
azelastine
solvate
Prior art date
Application number
CY20151100813T
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9938620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116693(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Limited filed Critical Cipla Limited
Publication of CY1116693T1 publication Critical patent/CY1116693T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Φαρμακευτική συνταγοποίηση η οποία περιλαμβάνει αζελαστίνη και φαρμακευτικώς αποδεκτό άλας, διαλύτωμα ή φυσιολογικώς λειτουργικό παράγωγο αυτής και κυκλεσονίδη.
CY20151100813T 2002-06-14 2015-09-16 Συνδυασμος αζελαστινης και κυκλεσονιδης CY1116693T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0213739A GB2389530B (en) 2002-06-14 2002-06-14 Pharmaceutical compositions
EP09075100.9A EP2075000B1 (en) 2002-06-14 2003-06-13 Combination of azelastine and ciclesonide

Publications (1)

Publication Number Publication Date
CY1116693T1 true CY1116693T1 (el) 2017-03-15

Family

ID=9938620

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20091100686T CY1109196T1 (el) 2002-06-14 2009-06-30 Συνδυασμος αζελαστινης και φλουτικαζονης
CY2014001C CY2014001I1 (el) 2002-06-14 2014-01-15 Συνδυασμος αζελαστινης και φλουτικαζονης
CY20141100132T CY1115386T1 (el) 2002-06-14 2014-02-20 Συνδυασμος αζελαστινης και μομεταζονης
CY20151100813T CY1116693T1 (el) 2002-06-14 2015-09-16 Συνδυασμος αζελαστινης και κυκλεσονιδης

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20091100686T CY1109196T1 (el) 2002-06-14 2009-06-30 Συνδυασμος αζελαστινης και φλουτικαζονης
CY2014001C CY2014001I1 (el) 2002-06-14 2014-01-15 Συνδυασμος αζελαστινης και φλουτικαζονης
CY20141100132T CY1115386T1 (el) 2002-06-14 2014-02-20 Συνδυασμος αζελαστινης και μομεταζονης

Country Status (29)

Country Link
US (10) US8168620B2 (el)
EP (3) EP2075000B1 (el)
KR (3) KR101301061B1 (el)
CN (1) CN1674910A (el)
AP (1) AP2004003192A0 (el)
AT (1) ATE428428T1 (el)
AU (3) AU2003244799B2 (el)
BR (1) BRPI0312128B8 (el)
CA (3) CA2489427C (el)
CR (1) CR7654A (el)
CY (4) CY1109196T1 (el)
DE (1) DE60327203D1 (el)
DK (3) DK1519731T3 (el)
ES (3) ES2456822T3 (el)
GB (1) GB2389530B (el)
GE (1) GEP20115143B (el)
HU (2) HUE027184T2 (el)
IL (3) IL165771A (el)
LU (1) LU92269I2 (el)
MA (1) MA27285A1 (el)
MX (1) MXPA04012666A (el)
NZ (2) NZ537246A (el)
PL (1) PL373001A1 (el)
PT (3) PT2075000E (el)
RU (1) RU2361593C3 (el)
SI (3) SI2075000T1 (el)
TN (1) TNSN04247A1 (el)
WO (1) WO2003105856A1 (el)
ZA (1) ZA200500331B (el)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1545548B1 (en) 2002-08-30 2010-06-30 Nycomed GmbH The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
SI2522365T1 (sl) * 2004-11-24 2017-02-28 Meda Pharmaceuticals Inc. Sestavki, ki obsegajo azelastin, in postopki njihove uporabe
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
CN101180038A (zh) 2005-03-23 2008-05-14 伊兰制药国际有限公司 纳米颗粒皮质类固醇和抗组胺药制剂
AR059358A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
JP6033677B2 (ja) 2009-03-17 2016-11-30 ナイコックス オフサルミクス， インコーポレイテッド セチリジンの眼科用製剤および使用方法
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
WO2010141834A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
WO2011035513A1 (zh) 2009-09-28 2011-03-31 Cao Hongguang 一种x射线图像探测装置
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
KR101261230B1 (ko) * 2010-11-29 2013-05-07 한림제약(주) 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
WO2012177251A1 (en) * 2011-06-22 2012-12-27 Adeda Therapeutics Company Limited Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
MX2014001940A (es) 2011-08-18 2014-03-27 Takeda Gmbh Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal.
KR101304341B1 (ko) * 2011-09-19 2013-09-11 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201121812D0 (en) * 2011-12-07 2012-02-01 Teva Branded Pharmaceutical Prod R & D Inc NAsal formulation
US20150044271A1 (en) * 2012-02-27 2015-02-12 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
MY196902A (en) * 2012-12-06 2023-05-09 Glenmark Pharmaceuticals Ltd Fixed dose pharmaceutical composition comprising mometasone and azelastine
KR20140081925A (ko) * 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
LT3043773T (lt) 2013-09-13 2021-10-11 Glenmark Specialty S.A. Stabilios fiksuotos dozės farmacinė kompozicija, kurioje yra mometazono ir olopatadino, skirta naudoti į nosį
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP2985027B1 (en) 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Nasal composition comprising mixture of hyaluronic acids and saline solution
EP2985019B1 (en) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
CN104173286B (zh) * 2014-09-10 2017-03-01 贵州云峰药业有限公司 氮卓斯汀组合物和用途
CN106806342A (zh) * 2015-12-01 2017-06-09 四川海思科制药有限公司 一种盐酸氮卓斯汀丙酸氟替卡松鼻喷剂药物组合物及其制备方法
ES2866175T3 (es) 2015-12-04 2021-10-19 Mexichem Fluor Sa De Cv Composición farmacéutica
EP3458156A4 (en) * 2016-05-17 2019-06-05 Mayo Foundation for Medical Education and Research MATERIALS AND METHODS FOR THE TREATMENT OF CHRONIC COUGH
CN109288790A (zh) * 2017-07-25 2019-02-01 健乔信元医药生技股份有限公司 鼻用医药组合物及其制备方法
TWI717539B (zh) * 2017-07-25 2021-02-01 健喬信元醫藥生技股份有限公司 鼻用醫藥組合物及其製備方法及鼻用複方懸浮液
CN107737105A (zh) * 2017-11-28 2018-02-27 贵州云峰药业有限公司 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺
CN107929738A (zh) * 2017-11-28 2018-04-20 贵州云峰药业有限公司 一种含盐酸氮卓斯汀的组合物
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
WO2021216915A1 (en) * 2020-04-22 2021-10-28 Topical Sinus Therapeutics, Inc. Topical preparations of drug delivery for nasal and sinus irrigation
CN115776885A (zh) * 2020-06-26 2023-03-10 La药研科技公司 用于治疗阿尔茨海默病和帕金森病的组合物和方法
WO2022098319A1 (en) * 2020-11-09 2022-05-12 Pharmactive Ilac Sanayi Ve Ticarey A.S. Pharmaceutical compositions comprising azelastine, beclomethasone and relevant excipients
WO2022108471A1 (ru) * 2020-11-20 2022-05-27 Герман Петрович БЕККЕР Средство для лечения и профилактики острых респираторных вирусных инфекций
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
WO2023192602A2 (en) * 2022-04-01 2023-10-05 Enalare Therapeutics Inc. Respiratory stimulant nasal formulations
WO2024063712A1 (en) * 2022-09-20 2024-03-28 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837464A (en) 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
DE1059906B (de) 1954-10-05 1959-06-25 Scherico Ltd Verfahren zur Herstellung von 1, 4-Pregnadienen
US3067197A (en) 1961-04-26 1962-12-04 Pfizer & Co C 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives
GB1047518A (en) 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
GB1159490A (en) 1966-02-09 1969-07-23 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
US3639434A (en) 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
IT1061787B (it) 1967-03-01 1983-04-30 Vismara Francesco Spa Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
GB1227992A (el) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
IT1034011B (it) 1969-06-26 1979-09-10 Vister Vismara Terapeutici S P Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
CH572914A5 (el) 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US3828080A (en) 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US3989686A (en) 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
GB1438940A (en) 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1440063A (en) 1972-08-11 1976-06-23 Glaxo Lab Ltd 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids
US4093721A (en) 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
GB1517278A (en) 1974-08-30 1978-07-12 Glaxo Lab Ltd Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates
YU54476A (en) 1975-03-31 1982-05-31 Taisho Pharmaceutical Co Ltd Process for obtaining 17-ester 21-halo-pregnane
CH628355A5 (de) 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4261984A (en) 1978-04-05 1981-04-14 Syntex (U.S.A.) Inc. 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4188385A (en) 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
US4263289A (en) 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4198403A (en) 1978-04-05 1980-04-15 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes
DE2817988A1 (de) 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
US4310466A (en) 1979-08-31 1982-01-12 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4267173A (en) 1979-11-05 1981-05-12 Schering Corporation Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
JPS56138200A (en) 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
GB2088877B (en) 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
ZA814440B (en) 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
SE449106B (sv) 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4607028A (en) 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4861765A (en) 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
ZA872389B (en) 1987-04-02 1987-11-25 Advanced Polymer Systems Inc Composition and method for delivering a steroid active ingredient
WO1989003390A1 (en) 1987-10-13 1989-04-20 Bodor Nicholas S Soft steroids having anti-inflammatory activity
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
DE3836579A1 (de) 1987-11-13 1989-05-24 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge
US5232919A (en) 1987-11-13 1993-08-03 Asta Pharma Aktiengesellschaft Azelastine embonate and compositions which contain it
US5271946A (en) 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
FR2644788B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
US5202316A (en) 1989-03-22 1993-04-13 Roussel Uclaf N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines
JPH07116215B2 (ja) 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
ES2055216T3 (es) 1989-05-05 1994-08-16 Asta Medica Ag Sales de la azelastina con solubilidad mejorada.
AU5640390A (en) 1989-06-16 1991-01-08 Upjohn Company, The Suramin type compounds and angiostatic steroids to inhibit angiogenesis
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE4025342A1 (de) 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
GB9103764D0 (en) 1991-02-22 1991-04-10 Glaxo Group Ltd Compositions
EP0656205B1 (en) * 1991-06-10 2001-08-08 Schering Corporation Non-chloroflurocarbon aerosol formulations
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
WO1994008551A2 (en) 1992-10-09 1994-04-28 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
CA2121435C (en) 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
DE4322703A1 (de) 1993-07-08 1995-01-12 Asta Medica Ag Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäureestern als Suspensionsstabilisatoren und Ventilschmiermittel
JP4208267B2 (ja) 1993-07-30 2009-01-14 キヤノン株式会社 制御装置
DE4328819A1 (de) 1993-08-27 1995-03-02 Hoechst Ag Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE4333920A1 (de) 1993-10-05 1995-04-13 Hoechst Ag Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
WO1995013810A1 (en) 1993-11-19 1995-05-26 Schering-Plough Healthcare Products Incorporated Nasal spray compositions containing oxymetazoline
US5576437A (en) 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
IL109656A (en) 1994-05-15 1998-02-22 Chemagis Ltd Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
GB9419536D0 (en) 1994-09-28 1994-11-16 Glaxo Inc Medicaments
AR002009A1 (es) 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
ES2179190T3 (es) 1995-04-14 2003-01-16 Smithkline Beecham Corp Inhalador dosificador para propianato de fluticasona.
JPH08291072A (ja) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 吸入用粉末製剤用結晶とその製造方法
JPH08291073A (ja) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
AU6392496A (en) * 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
GB9521696D0 (en) 1995-10-23 1996-01-03 Bayer Ag Combination of LTD4 receptor antagonists with glucocorticosteriods
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5707984A (en) 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
US5792758A (en) 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
SK89198A3 (en) 1995-12-29 1999-03-12 Glaxo Group Ltd Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives
ES2205177T5 (es) 1996-02-27 2007-08-01 Teijin Limited Composicion en polvo para administracion nasal.
US5985862A (en) 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US5981517A (en) 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
WO1997046243A1 (en) 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5830490A (en) 1997-04-04 1998-11-03 Weinstein; Robert E. Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物
AU8439998A (en) 1997-06-30 1999-01-25 Glaxo Group Limited Compounds
EP0903151A1 (en) 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5972327A (en) 1997-10-22 1999-10-26 Lin; Matthew M. Method of treating allergic rhinitis by delivering medication via the nasal vestibules
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
SE9704833D0 (sv) 1997-12-22 1997-12-22 Astra Ab New formulation
US5972920A (en) 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
FR2779841B1 (fr) 1998-06-15 2006-08-04 Peugeot Procede et dispositif de commande d'un actionneur electrique d'activation d'un systeme fonctionnel
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
SE9803770D0 (sv) 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6261539B1 (en) 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6294153B1 (en) * 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
EP1020233A1 (en) 1999-01-13 2000-07-19 The Procter & Gamble Company Dosing and delivering system
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
AU776608B2 (en) 1999-04-30 2004-09-16 Pfizer Products Inc. Glucocorticoid receptor modulators
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
US7413536B1 (en) 1999-09-14 2008-08-19 Xenoport, Inc. Substrates and screening methods for transport proteins
DE19947234A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IL150929A0 (en) 2000-01-28 2003-06-24 Rohm & Haas Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties
US6565832B1 (en) 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
CZ20022413A3 (cs) 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US20020133032A1 (en) 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0017988D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Novel process
JP2004504357A (ja) 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
WO2002011711A2 (en) 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
DZ3468A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyle) oxy!-11.beta.-hydroxy-16.alpha.-methyle-3-oxo-androst-1,4,-diene-17-acide carbothioique s-fluoromethyle ester utilise comme agent anti inflammatoire
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
JP2002053485A (ja) 2000-08-08 2002-02-19 Oshida Tetsuo アレルギー性疾患用医薬組成物
AR032362A1 (es) 2000-08-14 2003-11-05 Glaxo Group Ltd Formulacion topica estable de una emulsion de aceite en agua y proceso para su preparacion
WO2002026723A1 (en) 2000-09-29 2002-04-04 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
ZA200108461B (en) 2000-10-27 2002-06-06 Celanese Chem Europe Gmbh Process of telomerizing conjugated dienes.
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
WO2002036106A2 (de) 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden
YU33103A (sh) 2000-10-31 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Formulacija rastvora za inhalaciju sa soli tiotropijuma
PT1344526E (pt) 2000-12-22 2008-06-18 Nippon Shinyaku Co Ltd Profiláticos/remédios para doenças inflamatórias das vias aéreas
US20020132803A1 (en) 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6583180B2 (en) * 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
GB0105560D0 (en) 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
WO2002085296A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
CN1302007C (zh) 2001-04-30 2007-02-28 葛兰素集团有限公司 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物
ATE399174T1 (de) 2001-06-12 2008-07-15 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003013427A2 (en) 2001-08-03 2003-02-20 Smithkline Beecham Corporation A method for preparing fluticasone derivatives
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
KR20040068544A (ko) 2001-11-05 2004-07-31 더 브리검 앤드 우먼즈 하스피털, 인크. 아테롬성 동맥경화증의 예후 표지로서의 가용성 ｃｄ40ｌ(ｃｄ154)
GB0127160D0 (en) 2001-11-12 2002-01-02 Glaxo Group Ltd Novel compounds
WO2003042229A1 (en) 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
DK1467762T3 (da) 2001-12-05 2006-04-10 Alcon Inc Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
JP2005523268A (ja) 2002-02-04 2005-08-04 グラクソ　グループ　リミテッド グルココルチコイドおよびβ２−アドレナリン受容体アゴニストを含む吸入用製剤
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP3691459B2 (ja) 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
GB0217504D0 (en) 2002-07-29 2002-09-04 Novartis Ag Organic compounds
US7244742B2 (en) 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
EP1545548B1 (en) 2002-08-30 2010-06-30 Nycomed GmbH The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20040235807A1 (en) 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
WO2005030331A1 (en) 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
SI2522365T1 (sl) 2004-11-24 2017-02-28 Meda Pharmaceuticals Inc. Sestavki, ki obsegajo azelastin, in postopki njihove uporabe
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
GB0507165D0 (en) 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
WO2007061454A1 (en) 2005-11-22 2007-05-31 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
GB0615108D0 (en) 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
AU2009302362A1 (en) * 2008-10-10 2010-04-15 Merck Sharp & Dohme Corp. Corticosteroid compositions for use in treating diseases of the upper and lower airway passages

Also Published As

Publication number Publication date
TNSN04247A1 (en) 2007-03-12
GB2389530B (en) 2007-01-10
ES2545205T3 (es) 2015-09-09
US8933060B2 (en) 2015-01-13
SI2072051T1 (sl) 2014-07-31
BRPI0312128B1 (pt) 2018-01-30
WO2003105856A1 (en) 2003-12-24
AU2009243422A1 (en) 2009-12-17
KR20050024362A (ko) 2005-03-10
US8318709B2 (en) 2012-11-27
EP1519731B1 (en) 2009-04-15
DK2072051T3 (da) 2014-04-14
SI1519731T1 (sl) 2009-10-31
EP2072051B1 (en) 2014-01-29
KR101119895B1 (ko) 2012-02-22
GB2389530A (en) 2003-12-17
EP2075000A1 (en) 2009-07-01
IL165771A0 (en) 2006-01-15
US8304405B2 (en) 2012-11-06
SI2075000T1 (sl) 2015-10-30
US8168620B2 (en) 2012-05-01
MA27285A1 (fr) 2005-04-01
ES2456822T3 (es) 2014-04-23
IL216931A0 (en) 2012-01-31
IL216932A0 (en) 2012-01-31
KR20110113781A (ko) 2011-10-18
CR7654A (es) 2007-10-22
PT1519731E (pt) 2009-07-13
US9901585B2 (en) 2018-02-27
CA2779630A1 (en) 2003-12-24
DK2075000T3 (da) 2015-09-14
ES2324910T3 (es) 2009-08-19
CA2779630C (en) 2014-01-28
AU2009243420B2 (en) 2012-10-11
BRPI0312128B8 (pt) 2021-05-25
IL165771A (en) 2014-06-30
IL216932A (en) 2014-09-30
RU2361593C3 (ru) 2022-04-04
CA2779633A1 (en) 2003-12-24
AU2009243422C1 (en) 2014-01-09
CA2489427A1 (en) 2003-12-24
US20130029951A1 (en) 2013-01-31
NZ574658A (en) 2010-09-30
HUS1300032I1 (hu) 2017-10-30
CY2014001I1 (el) 2014-07-02
LU92269I2 (fr) 2013-10-22
ATE428428T1 (de) 2009-05-15
PT2072051E (pt) 2014-04-07
ZA200500331B (en) 2006-07-26
EP1519731A1 (en) 2005-04-06
HUE027184T2 (en) 2016-08-29
KR101301558B1 (ko) 2013-09-04
US20090291143A1 (en) 2009-11-26
PT2075000E (pt) 2015-11-03
US20060025391A1 (en) 2006-02-02
IL216931A (en) 2015-11-30
BR0312128A (pt) 2005-04-05
KR20110113782A (ko) 2011-10-18
AU2003244799B2 (en) 2009-09-10
CY1109196T1 (el) 2014-07-02
US8163723B2 (en) 2012-04-24
AU2003244799A1 (en) 2003-12-31
US8937057B2 (en) 2015-01-20
MXPA04012666A (es) 2005-09-30
US20100331289A1 (en) 2010-12-30
US20090318397A1 (en) 2009-12-24
AU2009243420A1 (en) 2009-12-24
NZ537246A (en) 2007-09-28
US20150224116A1 (en) 2015-08-13
CA2779633C (en) 2015-11-03
US20150072010A1 (en) 2015-03-12
EP2075000B1 (en) 2015-07-22
RU2361593C2 (ru) 2009-07-20
CA2489427C (en) 2012-09-25
KR101301061B1 (ko) 2013-08-28
US20170035780A1 (en) 2017-02-09
RU2005100781A (ru) 2005-08-10
GEP20115143B (en) 2011-01-25
EP2072051A1 (en) 2009-06-24
PL373001A1 (en) 2005-08-08
US20150190405A1 (en) 2015-07-09
CY1115386T1 (el) 2017-01-04
US20130029952A1 (en) 2013-01-31
US9259428B2 (en) 2016-02-16
DK1519731T3 (da) 2009-08-03
AP2004003192A0 (en) 2004-12-31
CN1674910A (zh) 2005-09-28
GB0213739D0 (en) 2002-07-24
DE60327203D1 (de) 2009-05-28
AU2009243422B2 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
CY1116693T1 (el) Συνδυασμος αζελαστινης και κυκλεσονιδης
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
CY1121330T1 (el) Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
NO20043101L (no) Farmasoytiske blandinger av oralt aktive taxanderivater som har forsterket biotilgjenglighet
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1107176T1 (el) Συνθεσεις και μεθοδος για θεραπεια μολυνσης σε βοοειδη και χοιρους
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
DK1675591T3 (da) Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer
CY1108421T1 (el) Η χρηση σκευασματων μελοξικαμης στην κτηνιατρικη
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
SE0101932D0 (sv) Pharmaceutical combinations
CY1107605T1 (el) Θεραπευτικη αγωγη
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
PT1185253E (pt) Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
CY1112173T1 (el) Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας
NO20040611L (no) Ekspanderbar gastrisk retensjonsanordning.